Evidence-based Guideline 1-14 Version 2 - EDUCATION AND INFORMATION 2015

A Quality Initiative of the
Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)

Baseline Staging Tests in Primary Breast Cancer

Members of the Breast Cancer Disease Site Group

An assessment conducted in January 2015 put Evidence-based Series (EBS) 1-14 Version 2 in the Education and Information Section. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes. The PEBC has a formal and standardize process to ensure the currency of each document (PEBC Assessment & Review Protocol).

<table>
<thead>
<tr>
<th>Evidence-based Series (EBS) 1-14 Version 2, the resulting review report, consists of the following 4 parts:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Guideline Report Overview</td>
</tr>
<tr>
<td>2. Summary</td>
</tr>
<tr>
<td>3. Full Report</td>
</tr>
<tr>
<td>4. Document Assessment and Review Tool</td>
</tr>
</tbody>
</table>

and is available on the CCO Website on the PEBC Breast Cancer DSG page

Release Date: November 1, 2011

For information about the PEBC and the most current version of all reports, please visit the CCO Web site at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822  Fax: 905-526-6775  E-mail: ccopgi@mcmaster.ca

# Table of Contents

**Overview**
Guideline Report History ................................................................. iii
Guideline Review Summary .............................................................. iv

**Summary (April 2003)**
Guideline Questions ........................................................................ vi
Target Population ................................................................................ vi
Recommendations .............................................................................. vi
Methods ............................................................................................ vii
Key Evidence ....................................................................................... vii
Future research .................................................................................. viii
Contact Information ........................................................................... viii
Preamble: About Our Practice Guideline Reports. ................................ ix
Copyright ............................................................................................ ix
Disclaimer ........................................................................................... ix

**FULL REPORT (April 2003)**
Questions ........................................................................................ 1
Choice of Topic and Rationale ........................................................... 1
Methods ............................................................................................. 2
Results ................................................................................................. 3
Interpretative Summary ........................................................................ 7
Ongoing trials ..................................................................................... 8
DSG Consensus Process ..................................................................... 8
External Review .................................................................................. 9
Future research .................................................................................. 12
Practice guideline ............................................................................... 12
Journal Reference ............................................................................... 12
Acknowledgements ............................................................................ 12
References .......................................................................................... 13
Appendix 1: Follow up after curative treatment for colorectal cancer .... 15
EBS 1-14 Document Assessment Review Tool .................................... 29
Evidence-based Guideline 1-14 Version 2

Baseline Staging Tests in Primary Breast Cancer

Guideline Report History

<table>
<thead>
<tr>
<th>GUIDELINE VERSION</th>
<th>SYSTEMATIC REVIEW</th>
<th>PUBLICATIONS</th>
<th>NOTES AND KEY CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original version</td>
<td>Search Dates</td>
<td>Data</td>
<td>Peer review publication(^1)</td>
</tr>
<tr>
<td>Update</td>
<td>Search Dates</td>
<td>Data</td>
<td>Updated Web publication</td>
</tr>
<tr>
<td>Apr 2003</td>
<td>2000-2003</td>
<td>No new data was added to original Full Report</td>
<td>New search yielded no additional studies</td>
</tr>
<tr>
<td>Version 2</td>
<td>Search Dates</td>
<td>Data</td>
<td>Updated Web publication</td>
</tr>
<tr>
<td>November 2011</td>
<td>2003 - 2009</td>
<td>New data found in Document and Assessment Review Tool</td>
<td>Added PET and PET-CT to all questions 2000 recommendations ENDORSED</td>
</tr>
</tbody>
</table>

Baseline Staging Tests in Primary Breast Cancer

Guideline Review Summary

Review Date: October 11, 2011

The 2000 guideline recommendations are ENDORSED

This means that the recommendations are still current and relevant for decision making.

OVERVIEW

Evidence-based Series History

This guidance document was originally released by the Program in Evidence-based Care, Cancer Care Ontario, in 2000 and its first update released in April 2003. In June 2009 the PEBC guideline update strategy was applied and the new updated document released in November 2011. The Summary and the Full Report in this version are the same as in the April 2003 version.

Update Strategy

Using the Document and Assessment Review Tool, the PEBC update strategy includes an updated search of the literature, review and interpretation of the new eligible evidence by clinical experts from the authoring guideline panel, and consideration of the guideline and its recommendations in response to the new available evidence.

DOCUMENT ASSESSMENT AND REVIEW RESULTS

Questions Considered

1. Does evaluation with bone scanning, liver ultrasonography, chest radiography, PET and PET-CT help to determine the extent of metastatic disease in women with newly diagnosed operable breast cancer who are otherwise asymptomatic?
2. In what stages of breast cancer is the prevalence of detectable metastatic disease high enough to justify routine testing with bone scanning, liver ultrasonography, chest radiography, PET, and PET-CT?
3. Is there a role for performing these tests before surgery or, for cases in which they are necessary, should they be performed only after surgery?
Literature Search and New Evidence

The new search (2003 to September 2009) yielded eight relevant new publications (one abstract and seven full texts) from eight randomized controlled trials (RCTs) evaluating initial staging techniques in breast cancer. Brief results of these publications are shown in the Document and Assessment Review Tool at the end of this report. The new search strategies excluded studies evaluating breast MRI because the Breast DSG decided that breast MRI studies would be better suited in a separate new guideline on breast imaging.

Impact on Guidelines and Its Recommendations

The new data supports the existing recommendations. It was determined that there is no need to update the guideline on liver ultrasound, chest x-ray, and bone scanning because they are older, well-established techniques that did not generate much data with this updated search and will be very unlikely to generate any new data in future. The existing guideline adequately addressed these techniques. Hence, the Breast Cancer DSG ENDORSED the 2003 recommendations on baseline staging tests in primary breast cancer. The PET data is new and sufficient for readers to be aware of what is available. At this time, there is no urgency to update the guideline with this new information on PET. Breast MRI is another technique that was not included in this version because it will be the subject of a separate guideline on breast imaging. Given that no new evidence is likely to arise, it is the consensus of the group that CT is a reasonable alternative in high risk (stage III) women.
Baseline Staging Tests in Primary Breast Cancer
Practice Guideline Report # 1-14

Members of the Breast Cancer Disease Site Group


Report Date: April 23, 2003

SUMMARY

Guideline Questions

- Does evaluation with bone scanning, liver ultrasonography and chest radiography help to determine the extent of metastatic disease in women with newly diagnosed operable breast cancer who are otherwise asymptomatic?
- In what stages of breast cancer is the prevalence of detectable metastatic disease high enough to justify routine testing with bone scanning, liver ultrasonography and chest radiography?
- Is there a role for performing these tests before surgery or, for cases in which they are necessary, should they be performed only after surgery?

Target Population

The following recommendations apply to women with newly diagnosed breast cancer who have undergone surgical resection and who have no symptoms, physical signs or biomedical evidence of metastases.

Recommendations

- Routine bone scanning, liver ultrasonography and chest radiography are not indicated before surgery.
- In women with intraductal and pathological stage I tumours, routine bone scanning, liver ultrasonography and chest radiography are not indicated as part of baseline staging.
- In women who have pathological stage II tumours, a postoperative bone scan is recommended as part of baseline staging. Routine liver ultrasonography and chest radiography are not indicated in this group but could be considered for patients with four or more positive lymph nodes.
In women with pathological stage III tumours, bone scanning, liver ultrasonography and chest radiography are recommended postoperatively as part of baseline staging.

In women for whom treatment options are restricted to tamoxifen or hormone therapy, or for whom no further treatment is indicated because of age or other factors, routine bone scanning, liver ultrasonography and chest radiography are not indicated as part of baseline staging.

Methods

Relevant evidence was identified by a systematic search of MEDLINE (1966-April 2003) and the Cochrane Library (Issue 1, 2003). Reports of case series in which 1) newly-diagnosed breast cancer patients were evaluated by bone scan, liver ultrasound or chest radiograph and 2) the number of cases positive for metastases were reported by stage of disease were eligible for inclusion in the overview of the evidence.

Evidence was selected and reviewed by one member of the Breast Cancer Disease Site Group and one member of the Practice Guidelines Initiative research staff. This practice guideline has been reviewed and approved by the Breast Cancer Disease Site Group, which comprises surgeons, medical oncologists, radiation oncologists, epidemiologists, a pathologist, a medical sociologist and community representatives.

External review of the original practice guideline report by Ontario practitioners was obtained through a mailed survey. Final approval of the original guideline was obtained from the Practice Guidelines Coordinating Committee. The Practice Guideline Initiative has a formal standardized process to ensure the currency of each guideline report. This consists of the periodic review and evaluation of the scientific literature, and where appropriate, integration of this literature with the original guideline information.

Key Evidence

- Eleven studies of bone scanning reported between 1972 and 1980 involved a total of 1307 women; bone scans detected skeletal metastases in 6.8% of those with stage I disease, in 8.8% with stage II, and in 24.5% with stage III. A total of 5407 women participated in nine studies of bone scanning reported between 1985 and 1995; in these studies, bone scans detected skeletal metastases in 0.5% of women with stage I disease, in 2.4% with stage II, and in 8.3% with stage III.

- Among 1625 women in four studies of liver ultrasound reported between 1988 and 1993, liver ultrasound detected hepatic metastases in no patients with stage I disease, in 0.4% with stage II, and in 2.0% with stage III.

- Among 3884 cases in two studies published in 1988 and 1991, chest radiographs detected lung metastases in 0.1% of stage I patients, in 0.2% of stage II, and in 1.7% of stage III.

- False-positive rates ranged from 10 to 22% for bone scanning, 33 to 66% for liver ultrasonography, and 0 to 23% for chest radiography. The false-negative rate for bone scanning was approximately 10%.

Future Research

Future studies should focus on the relationship between nodal status and the rates of detection of metastases by routine baseline testing with bone scan, liver ultrasound and chest radiograph.

For further information about this practice guideline, please contact:
Dr. Wendy Shelley; Co-chair, Breast Cancer Disease Site Group; Kingston Regional Cancer Centre, 25 King St W, Kingston ON, K7L 5P9; Telephone: 613-544-2631 x4502; Fax: 613-546-8209; E-mail: wendy.shelley@krcc.on.ca
or
Maureen Trudeau; Co-chair, Breast Cancer Disease Site Group; Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, Toronto ON, M4N 3M5; Telephone 416-480-5145; FAX 416-217-1338; E-mail: maureen.trudeau@tsrcc.on.ca.

The Practice Guidelines Initiative is sponsored by:
Cancer Care Ontario & the Ontario Ministry of Health and Long-term Care.
Visit http://www.cancercare.on.ca/ for all additional Practice Guidelines Initiative reports.
PREAMBLE: About Our Practice Guideline Reports

The Practice Guidelines Initiative (PGI) is a project supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care, as part of the Program in Evidence-based Care. The purpose of the Program is to improve outcomes for cancer patients, to assist practitioners to apply the best available research evidence to clinical decisions, and to promote responsible use of health care resources. The core activity of the Program is the development of practice guidelines by multidisciplinary Disease Site Groups of the PGI using the methodology of the Practice Guidelines Development Cycle. \(^1\) The resulting practice guideline reports are convenient and up-to-date sources of the best available evidence on clinical topics, developed through systematic reviews, evidence synthesis, and input from a broad community of practitioners. They are intended to promote evidence-based practice.

This practice guideline report has been formally approved by the Practice Guidelines Coordinating Committee, whose membership includes oncologists, other health providers, patient representatives, and Cancer Care Ontario executives. Formal approval of a practice guideline by the Coordinating Committee does not necessarily mean that the practice guideline has been adopted as a practice policy of CCO. The decision to adopt a practice guideline as a practice policy rests with each regional cancer network that is expected to consult with relevant stakeholders, including CCO.

Reference:


For the most current versions of the guideline reports and information about the PEBC, please visit the CCO Web site at:

http://www.cancercare.on.ca

For more information, contact our office at:

Phone: 905-527-4322 ext. 42822  Fax: 905-526-6775

E-mail: ccopgi@mcmaster.ca

Copyright

This guideline is copyrighted by Cancer Care Ontario; the guideline and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer

Care has been taken in the preparation of the information contained in this document. Nonetheless, any person seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or warranties of any kind whatsoever regarding their content or use or application and disclaims any responsibility for their application or use in any way.
Baseline Staging Tests in Primary Breast Cancer
Practice Guideline Report # 1-14

Members of the Breast Cancer Disease Site Group


Report Date: April 23, 2003

FULL REPORT

I. QUESTIONS
1. Does evaluation with bone scanning, liver ultrasonography and chest radiography help to determine the extent of metastatic disease in women with newly diagnosed operable breast cancer who are otherwise asymptomatic?
2. In what stages of breast cancer is the prevalence of detectable metastatic disease high enough to justify routine testing with bone scanning, liver ultrasonography and chest radiography?
3. Is there a role for performing these tests before surgery or, for cases in which they are necessary, should they be performed only after surgery?

II. CHOICE OF TOPIC AND RATIONALE
Over 7000 women will develop breast cancer each year in the province of Ontario (1). These patients will all undergo some sort of staging work-up at the time of diagnosis. One of the main purposes of staging is to rule out distant disease that would render the patient incurable with conventional therapy. Staging may occasionally occur before surgery, but is more commonly performed after surgery at the hospital where primary therapy is given. In many cases, these investigations may be repeated at secondary or tertiary referral centres.

Occasionally, false-positive results occur, leading to other expensive tests that negate the results of the original test. These staging tests are expensive (Table 1), time consuming and anxiety provoking. Although it is recognized that women with seemingly localized breast cancer may at some point develop metastatic disease, the clinical experience of the members of the Breast Cancer Disease Site Group (DSG) was that the prevalence of detectable metastases at initial diagnosis is very low in most stages of the disease. Hence, the Breast Cancer DSG decided to carefully review the evidence and indications for routine testing.
consisting of bone scan, liver ultrasound and chest radiograph in the asymptomatic woman who has undergone surgery for breast cancer.

Table 1. Costs of baseline staging tests, from the Ontario Health Insurance Plan fee schedule (Canadian dollars).

<table>
<thead>
<tr>
<th>Test</th>
<th>Technical Fee</th>
<th>Professional Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone Scan</td>
<td>$103.80</td>
<td>$48.10</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>$48.80</td>
<td>$29.10</td>
</tr>
<tr>
<td>Chest Radiograph</td>
<td>$21.91</td>
<td>$8.80</td>
</tr>
</tbody>
</table>

Staging in cancer, and more specifically breast cancer, has been a cornerstone in the management of this disease. Some of the reasons cited for baseline testing include: to predict prognosis, to ensure correct treatment, to reassure the patient, to serve as a baseline for follow-up tests, and to help compare results with those from other centres. In the early 1970's and 1980's, surgeons ordered these tests routinely before surgery to decide on whether mastectomy was appropriate. The routine use of these tests persisted over time but they were ordered more in the postoperative period. Though it has become more apparent over the years that the yield of staging tests, whether they are performed before or after surgery, is exceedingly low, the practice has persisted. However, staging tools are in a continuous state of evolution. The tests of today are more sensitive than in the past, thanks both to technical improvements and to the development of newer tests, such as magnetic resonance imaging (MRI) and computerized tomography (CT). A study in women at high risk for metastases who were being considered for transplant demonstrated that a very aggressive staging program can uncover disease not recognized by standard tests (2). This practice guideline report, however, will limit itself to discussing commonly used techniques in breast cancer staging, i.e., bone scan, abdominal ultrasound and chest radiograph.

In the 1970's, several studies of bone scanning detected quite high rates of metastatic disease in stage I and II cases, ranging from 3.4% to 35.5% (3-6). These studies were based on small numbers of cases, but were quoted frequently and helped to create controversy about staging. Subsequent studies with thousands of patients have rebutted these early data and have shown an exceedingly low rate of true bone scan abnormality. These studies, as well as reports concerning liver ultrasound and chest radiographs, are discussed below.

III. METHODS
Guideline Development
This practice guideline report was developed by the Practice Guidelines Initiative (PGI) of Cancer Care Ontario's Program in Evidence-based Care, using the methods of the Practice Guidelines Development Cycle (7). Evidence was selected and reviewed by members of the Breast Cancer DSG and methodologists. Members of the Breast DSG disclosed potential conflict of interest information.

The practice guideline report is a convenient and up-to-date source of the best available evidence on baseline staging tests in primary breast cancer, developed through systematic reviews, evidence synthesis and input from practitioners in Ontario. The body of evidence in this report is primarily comprised of mature randomized controlled trial data; therefore, recommendations by the DSG are offered. The report is intended to promote evidence-based practice. The Practice Guidelines Initiative is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.
External review by Ontario practitioners was obtained through a mailed survey consisting of items that address the quality of the draft practice guideline report and recommendations, and whether the recommendations should serve as a practice guideline. Final approval of the original guideline report was obtained from the Practice Guidelines Coordinating Committee.

The Practice Guideline Initiative has a formal standardized process to ensure the currency of each guideline report. This process consists of the periodic review and evaluation of the scientific literature, and where appropriate, integration of this literature with the original guideline information.

**Literature Search Strategy**

The MEDLINE and CANCERLIT databases (Ovid) were searched from 1966 to July 1998 using the MeSH headings “breast neoplasms”, “neoplasm staging”, “neoplasm metastasis”, “bone neoplasms/sc”, “liver neoplasms/sc” and “lung neoplasms/sc” and the textwords “preop:”, “stag:” and “baseline”. The search was updated in March and November 1999 and again in April 2000. These terms were also used to search the Cochrane Library (1999, Issues 1 and 4 and 2000, Issue 1). Articles found by the searches, cited in the relevant papers or known to the lead author of this practice guideline were retrieved and reviewed.

**Update**

The literature search was updated using subject headings (breast neoplasms, neoplasm staging, neoplasm metastases, bone neoplasms/sc, liver neoplasms/sc, lung neoplasms/sc, clinical trial[s], exp evaluation studies) and text words (breast, mammary, cancer, carcinoma, neoplasm, stage:, baseline). MEDLINE (2000-April 2003), the Cochrane Library (Issue 1, 2003) and the PDQ Clinical Trials Database (http://www.cancer.gov/search/clinical_trials/, accessed April 30, 2003) were searched for clinical trials of bone scanning, liver ultrasonography or chest radiography as staging tests in breast cancer.

**Inclusion Criteria**

Studies were eligible for inclusion in this overview of the evidence if they reported the number of women with newly diagnosed breast cancer who had metastases detected by bone scan, liver ultrasound or chest radiograph. These tests could be performed either before or after surgery. Both full reports and abstracts were eligible. Studies were included only if they reported the rates of positive tests by stage of disease and the staging system was similar to that currently in use (see Appendix I).

The primary outcome of interest was the detection rate, that is, the number of patients with abnormal tests that were indicative of metastases divided by the total number of patients tested. Detection rates were calculated by the guideline authors from data appearing in the study reports. Also of interest were the false-positive and the false-negative rates (8); these were given in some of the study reports reviewed for this guideline.

**Synthesizing the Evidence**

In order to get overall estimates of detection rates, results were pooled across studies. Study results were tabulated according to the stage of disease (I, II and III) and summed across studies. For each stage, the detection rates were pooled by dividing the total number of patients who tested positive for metastases by the total number of patients tested in the studies; the 95% confidence intervals (CI) were calculated for the pooled rates. Results from all stages were also pooled to produce an estimate of the overall detection rate.

**IV. RESULTS**
Literature Search Results

The literature search described above was not restricted by language; it uncovered three reports on bone scanning published in French and one in German. Because a large body of literature published in English was available and resources for translation were limited, these foreign-language publications were excluded from this practice guideline.

Twenty-two reports published in English of 21 case series evaluating one or more of the staging tests in question met the eligibility criteria above. These are summarized in Table 2.

Table 2. Studies eligible for inclusion in this report.

<table>
<thead>
<tr>
<th>Staging test evaluated</th>
<th>Number of studies</th>
<th>Reference numbers</th>
<th>Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone scan</td>
<td>20</td>
<td>3, 5, 9-26</td>
<td>Tables 3 &amp; 4</td>
</tr>
<tr>
<td>Liver ultrasound</td>
<td>4</td>
<td>21, 24, 27, 28</td>
<td>Table 5</td>
</tr>
<tr>
<td>Chest radiograph</td>
<td>2</td>
<td>21, 28</td>
<td>Table 6</td>
</tr>
</tbody>
</table>

Two studies evaluated all three staging tests (21, 22, 28). For one of these studies, Ahmed et al reported the data for bone scan (22) while liver ultrasound and chest radiograph results from the same series of patients appeared in a separate report by Glynne-Jones et al (28). Another study evaluated both bone scan and liver ultrasound (24).

Thirty-three additional studies evaluating bone scanning, four studies of liver ultrasonography and one study of chest radiography were not included in this report because they did not provide data in a format that would allow for analysis by stage of disease.

Update

No additional studies were found by update searches.

Bone Scan

The bone scan is the most commonly used method of detecting bone metastases. Although there is disagreement regarding its accuracy, it is more sensitive than skeletal radiographs (26). The bone scan is a safe procedure (29) that uses injection of the radiopharmaceutical technetium 99 MDP followed by scanning with a gamma camera. Sensitivity rates as high as 98% have been reported, but bone scans can also detect benign processes, and the false-positive rate ranges between 10 and 22% (29). The false-negative rate is estimated at 10% (29). The positive predictive value can be as low as 11.9% depending on how tight the definition of a positive scan is (29). All of these issues apply to staging well women with operable breast cancer. Furthermore, the prevalence of detectable metastatic disease in this population is exceedingly low.

Our literature search identified many studies that addressed the role of bone scans in early breast cancer. In general, studies up to 1980 (Table 3) tended to report higher rates of positive bone scans than those reported after 1980 (Table 4). To reflect this trend, most likely brought about by changes in practice and in bone scan technology, the Breast Cancer DSG felt that it was appropriate to divide the studies into older or more recent and arbitrarily chose 1980 as the cut-off date. Although the study methods used were not always clearly reported, data collection appeared to be retrospective in ten studies (9,12,18-23,25,26) and prospective in ten (3,5,10,11,13-17,24). Bone scans were performed before surgery in eight studies (10-13,15,16,21,25) and after surgery in four (9,14,22,26); the remaining studies included both preoperative and postoperative tests or did not state clearly when the tests were done.
Table 3. Bone scan results by stage of disease, from studies reported up to 1980.

<table>
<thead>
<tr>
<th>1st author (Reference)</th>
<th>Year of report</th>
<th># patients with positive bone scan/# patients in study (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stage I</td>
</tr>
<tr>
<td>Hoffman (9)</td>
<td>1972</td>
<td>2/10 (20%)</td>
</tr>
<tr>
<td>Citrin (5)</td>
<td>1975</td>
<td>6/49 (12%)</td>
</tr>
<tr>
<td>Campbell (3)</td>
<td>1976</td>
<td>15/50 (30%)</td>
</tr>
<tr>
<td>Gerber (10)</td>
<td>1977</td>
<td>2/73 (3%)</td>
</tr>
<tr>
<td>Baker (11)</td>
<td>1977</td>
<td>1/28 (4%)</td>
</tr>
<tr>
<td>Clark (12)</td>
<td>1978</td>
<td>5/71 (7%)</td>
</tr>
<tr>
<td>McNeil (13)</td>
<td>1978</td>
<td>0/37 (0%)</td>
</tr>
<tr>
<td>Nomura (14)</td>
<td>1978</td>
<td>1/14 (7%)</td>
</tr>
<tr>
<td>O’Connell (15)</td>
<td>1978</td>
<td>1/30 (3%)</td>
</tr>
<tr>
<td>Hahn (16)</td>
<td>1979</td>
<td>0/36 (0%)</td>
</tr>
<tr>
<td>Wilson (17)</td>
<td>1980</td>
<td>0/86 (0%)</td>
</tr>
</tbody>
</table>

Total pooled across studies | 33/484 | 52/594 | 56/229 | 141/1307 |

Percent positive (95% CI) | 6.8% (4.6, 9.0) | 8.8% (6.5, 11.1) | 24.5% (18.9, 30.1) | 10.8% (9.1, 12.5) |

NA, not available.
Table 4. Bone scan results by stage of disease, from studies reported after 1980.

<table>
<thead>
<tr>
<th>1st author (Reference)</th>
<th>Year of report</th>
<th># patients with positive bone scan/#patients in study (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stage I</td>
</tr>
<tr>
<td>Kunkler (18)</td>
<td>1985</td>
<td>1/66 (2%)</td>
</tr>
<tr>
<td>Khansur (19)</td>
<td>1987</td>
<td>0/92 (0%)</td>
</tr>
<tr>
<td>Coleman (20)</td>
<td>1988</td>
<td>0/271 (0%)</td>
</tr>
<tr>
<td>Ciatto (21)</td>
<td>1988</td>
<td>1/550 (0.2%)</td>
</tr>
<tr>
<td>Ahmed (22)</td>
<td>1990</td>
<td>2/80 (3%)</td>
</tr>
<tr>
<td>Kennedy (23)</td>
<td>1991</td>
<td>0/13 (0%)</td>
</tr>
<tr>
<td>Cox (24)</td>
<td>1992</td>
<td>1/122 (1%)</td>
</tr>
<tr>
<td>Brar (25)</td>
<td>1993</td>
<td>0/21 (0%)</td>
</tr>
<tr>
<td>Yeh (26)</td>
<td>1995</td>
<td>2/204 (1%)</td>
</tr>
<tr>
<td>Total pooled across studies</td>
<td></td>
<td>7/1419</td>
</tr>
</tbody>
</table>

Percent positive (95% CI) 0.5% (0.1, 0.9) 2.4% (1.8, 3.0) 8.3% (6.7, 9.9) 3.1% (2.6, 3.6)

NA, not available.

It is not possible to explain completely the differences in results between patients seen before 1980 and those seen after. In recent years, patients presenting to surgeons have smaller lesions; this would alter the composition of the stage I group by including more women with smaller tumours. In early studies, bone lesions that were called abnormal did not always progress to frank bone metastases and might not be designated malignant if reviewed now. Today, an abnormal bone scan would precipitate plain radiographs and possibly biopsy if there was any doubt about etiology. Nonetheless, both sets of studies show an increase in abnormalities as stage of disease increases. It is important that staging decisions be based on current information, and hence the results from Table 4 should be used for making clinical or policy decisions.

Liver Ultrasound
The liver is less frequently involved by metastatic breast cancer than bone (4,17). Tests to determine liver involvement include physical exam, liver function blood tests, liver scan, liver ultrasound, liver CT, and liver MRI. The evidence available to determine which modality is best is conflicting and this conflict is not completely resolved (1,24,25,27,30-32). Nonetheless, the test currently used most frequently for staging is ultrasound.

Table 5 summarizes the results of four studies of baseline ultrasound of the liver, tabulated by stage of disease. All of these were reported after 1980. Data were collected retrospectively in two studies (21,28) and prospectively in two (24,27). Liver scans were performed before surgery in two studies (21,27), after surgery in one (28) and before or after in the fourth (24). Based on these data, the chance of an abnormal test appears to be even lower than that observed in the bone scan studies.

Depending on how strictly one defines abnormalities in the liver, the false-positive rate may vary from 33% (2 of 6) up to 52% (11 of 21) (28) and is probably higher than one can expect currently. However, there are many benign incidental findings with routine...
ultrasound; in one study, 100 benign findings were noted among 346 patients (24).

There were no clear data exploring a relationship between liver ultrasound results and normal versus abnormal liver function tests.

Table 5. Liver ultrasound results by stage of disease at diagnosis of breast cancer.

<table>
<thead>
<tr>
<th>1st author (Reference)</th>
<th>Year of report</th>
<th># patients with positive liver scan/ #patients in study (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stage I</td>
</tr>
<tr>
<td>Ciatto (21)</td>
<td>1988</td>
<td>0/132 (0%)</td>
</tr>
<tr>
<td>Clark (27)</td>
<td>1988</td>
<td>0/110 (0%)</td>
</tr>
<tr>
<td>Glynne-Jones (28)</td>
<td>1991</td>
<td>0/54 (0%)</td>
</tr>
<tr>
<td>Cox (24)</td>
<td>1992</td>
<td>0/127 (0%)</td>
</tr>
<tr>
<td>Total pooled across studies</td>
<td></td>
<td>0/423</td>
</tr>
<tr>
<td>Percent positive (95% CI)</td>
<td></td>
<td>0%</td>
</tr>
</tbody>
</table>

Chest Radiograph

The lung, although not as common a site as bone for the development of metastatic disease, is still routinely assessed in staging the breast cancer patient. Only two studies have reported chest radiograph results by stage of disease, and their results are shown in Table 6. Both studies collected data retrospectively; chest radiographs were performed before surgery in one study (21) and after surgery in the other (28).

As for the other staging modalities, chest radiography was shown to have an appreciable false-positive rate of 23% (3 of 13) when equivocal results were considered. However, when stricter criteria were used for eight positive cases, none were false positives (28).

Table 6. Chest radiograph by stage of disease at diagnosis of breast cancer.

<table>
<thead>
<tr>
<th>1st author (Reference)</th>
<th>Year of report</th>
<th># patients with positive chest radiograph/ #patients in study (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stage I</td>
</tr>
<tr>
<td>Ciatto (21)</td>
<td>1988</td>
<td>1/873 (0.1%)</td>
</tr>
<tr>
<td>Glynne-Jones (28)</td>
<td>1991</td>
<td>0/64 (0%)</td>
</tr>
<tr>
<td>Total pooled across studies</td>
<td></td>
<td>1/937</td>
</tr>
<tr>
<td>Percent positive (95% CI)</td>
<td></td>
<td>0.1%</td>
</tr>
</tbody>
</table>

V. INTERPRETIVE SUMMARY

There have been many studies assessing the value of bone scan, liver ultrasound and chest radiograph in breast cancer staging. Studies where results were reported by conventional TNM stage have all been reviewed for this practice guideline. Those reported up to 1980 tended to demonstrate rates of positive bone scans that were higher than the rates found by studies reported after 1980. The yield of baseline testing increases with stage of disease but overall is very low for all three sites of metastases in asymptomatic patients. The pooled detection
rates (i.e. the proportion of tests that were positive for metastases) in stage I breast cancer, from studies published after 1980, were 0.5% for bone scan, 0% for liver ultrasound and 0.1% for chest radiograph. In women with stage II disease, 2.4% of bone scans, 0.4% of liver ultrasounds and 0.2% of chest radiographs detected metastases. Rates of positive tests for stage III disease were 8.3%, 2.0% and 1.7% for bone scan, liver ultrasound and chest radiograph, respectively. The strength of the available evidence lies not in study design, which in some cases is quite weak, but principally in the number of patients that have been studied: 5407 patients with bone scans, 1625 with liver ultrasounds and 3884 with chest x-rays and the corresponding narrow confidence intervals for the estimates of detection rate.

VI. ONGOING TRIALS
The Breast Cancer DSG is not aware of any ongoing, relevant randomized trials of baseline staging in primary breast cancer.

VII. BREAST CANCER DISEASE SITE GROUP CONSENSUS PROCESS
A poll of DSG members indicated that baseline testing (bone scan, liver ultrasound and chest radiograph) is currently being performed at diagnosis on virtually every woman with operable invasive breast cancer in Ontario. In some hospitals, even women with intraductal cancers have these tests performed. These tests may be repeated after referral to secondary or tertiary treatment centres. In some hospitals, staging tests may be performed prior to surgery; however, given that complete tumour and axillary-nodal staging cannot be known until after surgery, it would be more logical to perform the tests, if needed, after surgery. The systematic overview of the evidence summarized in this practice guideline demonstrates that these tests rarely detect metastases in asymptomatic women. However, there are a significant number of false-positive test results that oblige the physician to perform other more invasive tests. After reviewing this evidence, the Breast Cancer DSG agreed that it was time to rethink the strategy for baseline testing in the "well" operable woman with breast cancer. The DSG considered baseline testing to be a separate issue from the use of these tests as part of follow-up assessment after treatment for breast cancer, which has been dealt with in a published clinical practice guideline (33).

There are several arguments made in support of these tests: women may demand them; there may be medical-legal issues; doctors feel comfortable ordering them; and clearly there are certain subsets of patients that require them. Nonetheless, there are reasons for abandoning the routine use of these tests: the prevalence of metastatic disease is very low in early-stage disease; the tests are expensive, time consuming and anxiety provoking; women are being diagnosed at much earlier stages of disease than in the past; and finally, metastatic disease is incurable. Currently, the goal of treatment for metastatic disease is palliation. One of the main concerns resulting from not doing baseline staging tests is that a patient could be incorrectly classified, so that a woman thought to have stage I or II disease might in fact have stage IV (metastatic) disease. In this case, the woman might be treated inappropriately. The DSG agreed that while this type of error in staging would clearly be an unfortunate event, its occurrence would be relatively rare. Furthermore, such an error would not deny patients potentially curative treatments.

The Breast Cancer DSG has reviewed the research results summarized in this report in detail. Evidence from studies reported after 1980 was used as the basis for the draft recommendations because it was considered more relevant to current practice than was evidence from earlier studies. DSG members felt that tests that detected metastases in less than one percent of patients and also resulted in a significant number of false-positives were not clinically useful. Where to place the cut-off for detection rate was a subjective decision, but after discussion at a DSG meeting, the members agreed on one percent.
There were several areas where decision-making was easier than others. In stage I patients, where the yield for all tests was less than 1%, it seems appropriate to recommend the elimination of routine testing. Although studies of staging have not been performed in women with intraductal disease, there is good reason to assume that the yield from staging tests would be even less than in stage I cases. For this reason, the DSG recommends the elimination of staging tests in this group. Among stage III patients, the proportion of abnormal tests was higher, exceeding 1% for all three tests. In this group, the consensus was that the tests should be retained.

The longest discussion by the DSG concerned the use of staging tests in women with stage II breast cancer. The yield of positive results in this group was 2% for bone scan and less than 1% for ultrasound and chest radiograph. A good case could be made for retaining bone scanning and eliminating liver ultrasound and chest radiograph in this group. The DSG considered the possibility of dividing the stage II group according to size of tumour or number of positive lymph nodes (≤4 versus ≥4 positive nodes). This approach was based on the assumption that risk might vary across the range of stage II patients. For example, a larger number of positive nodes could be associated with a higher likelihood of detecting metastases with staging tests. However, data were not available to answer this question.

Finally, some discussion occurred concerning patients who, because of co-morbid illness, age or personal preference, would not be candidates for chemotherapy but would either be treated with tamoxifen or receive no further treatment after surgery (with or without radiotherapy). Because one of the main purposes of staging is to rule out distant disease that would render the patient incurable with conventional therapy, the DSG did not recommend the use of baseline staging tests in this group of patients, provided they were asymptomatic. In asymptomatic patients where the decision to use tamoxifen or hormone therapy, or to undergo no further treatment has already been made, there seems to be little need to perform staging tests, as the results would not change treatment.

The DSG discussed what other tests should be performed at the time of diagnosis. Although a review of the literature related to this topic was beyond the scope of the practice guideline, the DSG easily reached consensus on the following recommendations: in women with newly diagnosed breast cancer that has been resected, baseline testing should consist of a careful history, physical examination, complete blood count and liver function, serum calcium and renal function tests. Other specific tests may be ordered to assess abnormalities detected by the history, physical exam or laboratory tests. These tests will help the clinician decide whether further tests or imaging are needed. They will also help determine which patients can tolerate chemotherapy.

VIII. EXTERNAL REVIEW OF THE PRACTICE GUIDELINE REPORT
Draft Recommendations
Based on the evidence described above, the Breast Cancer DSG drafted the following recommendations:

Target population
The following recommendations apply to women with newly diagnosed breast cancer that has been resected, who have no symptoms or signs of metastases.

Draft Recommendations
- In women with intraductal and pathological stage I tumours, chest radiograph, bone scan and liver ultrasound are not indicated routinely.
- In women who have pathological stage II tumours, a bone scan should be ordered routinely. As pathologic confirmation of stage is required, this test should be ordered...
after surgery. Ultrasound of the liver and chest radiograph are not indicated routinely in this group.

- In women with pathological stage III tumours, routine bone scan, liver ultrasound and chest radiograph should be performed postoperatively.
- In asymptomatic patients who have undergone surgery for their breast cancer and where the treatment options are restricted to tamoxifen or no further treatment because of age or other factors, the use of routine staging should be discouraged.

Practitioner Feedback
Based on the evidence and the draft recommendations presented above, feedback was sought from Ontario clinicians.

Methods
In June 1999, practitioner feedback was obtained through a mailed survey of 147 practitioners in Ontario (48 medical oncologists, 39 radiation oncologists, 44 surgeons and 16 diagnostic radiologists). The survey consisted of 20 questions about the quality of the practice-guideline-in-progress report and whether the draft recommendations should be approved as a practice guideline. Written comments were invited. Follow-up reminders were sent at two weeks (postcard) and four weeks (complete package mailed again). The results of the survey have been reviewed by the Breast Cancer DSG.

Results
Key results of the practitioner feedback survey are summarized below in Table 7. Ninety-two (63%) questionnaires were returned. Seventy-one (43%) respondents indicated that they are responsible for the care of patients for whom the practice-guideline-in-progress report is relevant. Two respondents indicated that they were unsure, three left the question blank and one answered no but completed the remaining items, to give a total of 77 completed questionnaires. Forty-one respondents (45%) provided written comments.

Table 7: Responses to eight key items on the practitioner feedback survey.

<table>
<thead>
<tr>
<th>Item</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The rationale for developing a clinical practice guideline, as stated in the “Choice of Topic” section of the report, is clear.</td>
<td>75 (97%)</td>
</tr>
<tr>
<td>There is a need for a clinical practice guideline on this topic.</td>
<td>67 (87%)</td>
</tr>
<tr>
<td>The literature search is relevant and complete.</td>
<td>68 (90%)</td>
</tr>
<tr>
<td>The results of the trials described in the report are interpreted according to my understanding of the data.</td>
<td>68 (91%)</td>
</tr>
<tr>
<td>The draft recommendations in this report are clear.</td>
<td>70 (92%)</td>
</tr>
<tr>
<td>I agree with the draft recommendations as stated.</td>
<td>55 (74%)</td>
</tr>
<tr>
<td>This report should be approved as a practice guideline.</td>
<td>55 (75%)</td>
</tr>
</tbody>
</table>
If this report were to become a practice guideline, how likely would you be to make use of it in your own practice?

<table>
<thead>
<tr>
<th>Very likely or likely</th>
<th>Unsure</th>
<th>Unlikely or not at all likely</th>
</tr>
</thead>
<tbody>
<tr>
<td>54 (74%)</td>
<td>12 (16%)</td>
<td>7 (10%)</td>
</tr>
</tbody>
</table>

There was some variation among the specialty groups surveyed. Sixty percent of medical oncologists, 75% of radiation oncologists and 92% of surgeons agreed with the draft recommendations as stated. Only three radiologists completed the survey; two of these three agreed with the recommendations.

**Main Points Made as Comments**

1. Several respondents commented on the recommendations for baseline staging tests in women with stage II disease. Some questioned the need for bone scans in stage II patients when the yield is only 2-3%. Others were reluctant to discontinue routine chest radiographs and liver ultrasounds in this group, especially in patients who may have a higher probability of metastatic disease (e.g., patients with four or more positive lymph nodes).
2. Some practitioners were concerned about not performing imaging tests in older patients and those for whom chemotherapy is not recommended.
3. Practitioners asked if there is evidence to support the routine use of liver function, serum calcium and renal function tests at baseline.
4. A guideline on the use of routine imaging in follow-up was requested.
5. Some clinicians felt that the practice guideline was too rigid and dictated clinical judgement.

**Modifications/Actions**

1. Unfortunately, the evidence available does not address the differential value of the staging tests among subgroups of stage II patients. A qualifying statement was added to the recommendations for stage II patients suggesting that a chest radiograph and liver ultrasound could be considered for patients with four or more positive lymph nodes. A recommendation that the association between nodal status and the results of baseline staging tests be studied prospectively has also been added to the guideline report under the heading Future Research.
2. Further explanation for this recommendation was added to the DSG Consensus section of the guideline report. A statement, that one of the main purposes of staging is to rule out distant disease that would render the patient incurable with conventional therapy, was added to the Choice of Topic & Rationale section.
3. The issue of baseline blood tests was not directly addressed by the practice guideline. However, it was discussed by the DSG during the development of the guideline and some consensus-based recommendations were included in the discussion section of the practice-guideline-in-progress report. Following practitioner feedback, the rationale for baseline blood tests was added to the Disease Site Group Consensus section of the guideline report.
4. The Breast Cancer DSG endorses the recommendation of the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer that routine radiographic investigations should not be carried out for the purpose of detecting distant metastases during follow-up after treatment for breast cancer (33).
5. The DSG feels that the recommendations are consistent with the evidence from the literature, but recognizes that some patients and physicians may choose to use a different approach to staging than is suggested by the guideline. In order to make it clear
that the practice guideline is intended to assist rather than to dictate treatment
decisions, the language in the recommendations was modified from "should be
performed/ordered" to "is recommended".

IX. FUTURE RESEARCH
Future studies should focus on the relationship between nodal status and the rates of
detection of metastases by routine baseline testing with bone scan, liver ultrasound and chest
radiograph.

X. PRACTICE GUIDELINE
Target Population
The following recommendations apply to women with newly diagnosed breast cancer who
have undergone surgical resection and who have no symptoms, physical signs or biomedical
evidence of metastases.

Recommendations
- Routine bone scanning, liver ultrasonography and chest radiography are not indicated
  before surgery.
- In women with intraductal and pathological stage I tumours, routine bone scanning, liver
  ultrasonography and chest radiography are not indicated as part of baseline staging.
- In women who have pathological stage II tumours, a postoperative bone scan is
  recommended as part of baseline staging. Routine liver ultrasonography and chest
  radiography are not indicated in this group but could be considered for patients with four
  or more positive lymph nodes.
- In women with pathological stage III tumours, bone scanning, liver ultrasonography and
  chest radiography are recommended postoperatively as part of baseline staging.
- In women for whom treatment options are restricted to tamoxifen or hormone therapy,
or for whom no further treatment is indicated because of age or other factors, routine
  bone scanning, liver ultrasonography and chest radiography are not indicated as part of
  baseline staging.

XI. JOURNAL REFERENCE
Myers RE, Johnston M, Pritchard K, Levine M, Oliver T and the Breast Cancer Disease Site
Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in

XII. ACKNOWLEDGMENTS
The Breast Cancer Disease Site Group would like to thank Robert Myers for taking the lead in
drafting, revising and updating this practice guideline, with the assistance of Mary Johnston.

For a complete list of the Breast Disease Site Group members, please visit the CCO Web site
at http://www.cancercare.on.ca/.
REFERENCES

20. Coleman RE, Rubens RD, Fogelman I. Reappraisal of the baseline bone scan in breast...
Appendix 1. Stage grouping for breast cancer.

TNM STAGING

Primary Tumor (T)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tx</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>Tis</td>
<td>Carcinoma in situ: Intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no tumor</td>
</tr>
<tr>
<td>T1</td>
<td>Tumor 2 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T1mic</td>
<td>Microinvasion 0.1 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T1a</td>
<td>More than 0.1 cm but not more than 0.5 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T1b</td>
<td>More than 0.5 cm but not more than 1 cm in greatest dimension</td>
</tr>
<tr>
<td>T1c</td>
<td>More than 1 cm but not more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor more than 2 cm but not more than 5 cm in greatest dimension</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor more than 5 cm in greatest dimension</td>
</tr>
<tr>
<td>T4</td>
<td>Tumor of any size with direct extension to chest wall or skin</td>
</tr>
<tr>
<td>T4a</td>
<td>Extension to chest wall</td>
</tr>
<tr>
<td>T4b</td>
<td>Edema (including peau d’orange) or ulceration of the skin of the breast or satellite skin nodules confined to same breast</td>
</tr>
<tr>
<td>T4c</td>
<td>Both (T4a and T4b)</td>
</tr>
<tr>
<td>T4d</td>
<td>Inflammatory carcinoma</td>
</tr>
</tbody>
</table>

Regional Lymph Nodes (N)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nx</td>
<td>Regional lymph nodes cannot be assessed (e.g., previously removed)</td>
</tr>
<tr>
<td>No</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis to movable ipsilateral axillary lymph node(s)</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to other structures</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis to ipsilateral internal mammary lymph node(s)</td>
</tr>
</tbody>
</table>

Distant Metastasis (M)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mx</td>
<td>Presence of distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis (includes metastasis to ipsilateral supraclavicular lymph nodes)</td>
</tr>
</tbody>
</table>

STAGE GROUPING

<table>
<thead>
<tr>
<th>Stage 0 Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
</tr>
<tr>
<td>Stage II A</td>
<td>T0</td>
<td>N1</td>
</tr>
<tr>
<td>Stage II B</td>
<td>T1</td>
<td>N0</td>
</tr>
<tr>
<td>Stage III A</td>
<td>T2</td>
<td>N0</td>
</tr>
<tr>
<td>Stage III B</td>
<td>T3</td>
<td>N0</td>
</tr>
<tr>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
</tr>
</tbody>
</table>

EBS 1-14 Document Assessment and Review Tool.

**DOCUMENT ASSESSMENT AND REVIEW TOOL**

<table>
<thead>
<tr>
<th>Number and title of document under review</th>
<th>1-14 Baseline Staging Tests in Primary Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of current version</td>
<td>October 2003</td>
</tr>
<tr>
<td>Clinical reviewer</td>
<td>Dr. Caroline Hamm</td>
</tr>
<tr>
<td>Research coordinator</td>
<td>Rovena Tey</td>
</tr>
<tr>
<td>Date initiated</td>
<td>26 June 2009, initiated revisions on 24 June 2010 &amp; 25 Jan 2011</td>
</tr>
<tr>
<td>Date and final results / outcomes</td>
<td>24 June 2011</td>
</tr>
</tbody>
</table>

Beginning at question 1, below, answer the questions in sequential order, following the instructions in the black boxes as you go.

1. Is there still a need for a guideline covering one or more of the topics in this document? Answer Yes or No, and explain if necessary:

   1. YES

   If No, then the document should be **ARCHIVED** with no further action; **go to 11**. If Yes, then **go to 2**.

2. Are all the current recommendations based on the current questions **definitive** or **sufficient**, and have less than **5 years elapsed** since the latest search? Answer Yes or No, and explain if necessary:

   2. NO (not definitive, not sufficient, >5 y elapsed)

   • needs an update to include new techniques (breast MRI and PET scanning)
   • old techniques (bone scanning, liver ultrasonography, chest radiography) are still valid and standard

   If Yes, the document can be **ENDORSED** with no further action; **go to 11**. If No, **go to 3**.

3. Is there expected or known evidence that contradicts the current recommendations, such that they may cause harm or lead to unnecessary or improper treatment if followed? Answer Yes or No, and explain if necessary, providing references of known evidence:

   3. NO

   If Yes, the document should be taken off the website as soon as possible. A **WARNING** should be put in its place informing a user that the document is only available by email, with a brief explanation of the reasons. If No, **go to 4**.

4. Do current resources allow for an updated literature search to be conducted at this time? Answer Yes or No, and explain as necessary. Provide an expected date of completion of the updated search, if applicable:

   4. YES

   • updated search to be completed by end of February 2010

   If No, a **DEFERRAL** should be placed on the document indicating it cannot be updated at this time, but will be reviewed again on a yearly basis. If Yes, **go to 5**.

5a. List below any new, relevant questions that have arisen since the last version of the document. List any changes to the original research questions that now must be considered. Changes are in **BOLD**.

   **Changes to the original research questions:**
   • Add PET and PET-CT to all Qs

   **Questions:**
   1. Does evaluation with bone scanning, liver ultrasonography, and chest radiography, PET and PET-CT help to determine the extent of metastatic disease in women with newly diagnosed operable breast cancer who are otherwise asymptomatic?
   2. In what stages of breast cancer is the prevalence of detectable metastatic disease high enough to justify routine testing with bone scanning, liver ultrasonography, and chest radiography, PET, and PET-CT?
   3. Is there a role for performing these tests before surgery or, for cases in which they are necessary, should
they be performed only after surgery?

5b. List below any changes to the selection criteria in the original version made necessary by new questions, changes to existing questions, or changes in available evidence (e.g., limit a search to randomized trials that originally included non-randomized evidence). Changes are in BOLD.

Include all study types (unlikely to find a lot of RCTs) and meta-analyses. Search for articles published since 2003 for all staging tests including breast MRI and PET scanning.

Inclusion Criteria:
Studies and meta-analyses were eligible for inclusion in this overview of the evidence if they reported the number of women with newly diagnosed breast cancer who had metastases detected by bone scan, liver ultrasound, or chest radiograph, PET, or PET-CT. These tests could be performed either before or after surgery. Both full reports and abstracts were eligible. Studies were included only if they reported the rates of positive tests by stage of disease and the staging system was similar to that currently in use.

The primary outcome of interest was the detection rate, that is, the number of patients with abnormal tests that were indicative of metastases divided by the total number of patients tested. Detection rates were calculated by the guideline authors from data appearing in the study reports. Also of interest were sensitivities, specificities, change in stage or management, and the false-positive and the false-negative rates; these were given in some of the study reports reviewed for this guideline.

Other documents to consider:
• a couple of meta-analyses from 2008

• HTA UK report - Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers (Oct 2007; Vol. 11: No. 44) by K Facey, I Bradbury, G Laking and E Payne


• CCO/PEBC guideline - 1-19 Management of locally advanced breast cancer (imaging section), [ongoing]

5c. Conduct an updated literature search based on that done for the current version and modified by 5a and 5b above. Report the results below.

Full Selection Criteria, including types of evidence (e.g., randomized, non-randomized, etc.):

Studies and meta-analyses were eligible for inclusion in this overview of the evidence if they reported the number of women with newly diagnosed breast cancer who had metastases detected by bone scan, liver ultrasound, chest radiograph, PET, or PET-CT. These tests could be performed either before or after surgery. Both full reports and abstracts were eligible. Studies were included only if they reported the rates of positive tests by stage of disease and the staging system was similar to that currently in use.

The primary outcome of interest was the detection rate, that is, the number of patients with abnormal tests that were indicative of metastases divided by the total number of patients tested. Detection rates were calculated by the guideline authors from data appearing in the study reports. Also of interest were sensitivities, specificities, change in stage or management, and the false-positive and the false-negative rates; these were given in some of the study reports reviewed for this guideline.

Search Period:
• 2003 to 14 Sep 2009 (Embase + Medline)
• 2006 to 2009 (ASCO)
• 2007 to 2009 (San Antonio BCS)

Brief Summary/Discussion of New Evidence:
Of 438 total hits from Medline + Embase and 1458 total hits from ASCO + San Antonio conference abstract
searches, 8 references (1 abstract + 7 full text) representing 8 studies evaluated initial staging techniques in breast cancer. 7 studies evaluated either PET or PET-CT, and 1 study evaluated bone scanning, chest radiography, and liver US.

<table>
<thead>
<tr>
<th>Diagnostic/ Staging test</th>
<th>Study type</th>
<th>Population</th>
<th>Outcomes</th>
<th>Brief results</th>
<th>Reference</th>
</tr>
</thead>
</table>
| PET-CT vs MRI, chest X-ray, liver US, bone scan, biopsy | Prospective | Newly diagnosed, noninflammatory, large primary (>3 cm) BC | Detection rate, change in stage | • PET-CT detection rates:  
  o Stage IIIB = 65%  
  o Stage IIIA = 17%  
  o Stage IIIB = 3%  
  o Stage IIIC = 5%  
  o Stage IV = 10%  
  • PET led to a change in the initial staging in 42% of patients. | Fuster D, et al. 2008 |
| FDG-PET-CT vs biopsy, follow-up scans | Retrospective | Initial diagnosis of BC | Detection rate | • FDG-PET-CT detection rates:  
  o Stage I = 28%  
  o Stage II = 53%  
  o Stage III = 19% | Khan Q, et al. 2007. [abstract] |
| FDG-PET-CT vs mammogram, US, chest radiography, bone scintigraphy, CT, biopsy | Prospective | Initial assessment of patients with stage 2-3 BC | Change in stage, change in management | • PET-CT modified the initial stage in 18% of patients  
  • The modified staging altered the treatment plan for 13% of patients | Groheux D, et al. 2008 |
| FDG-PET-CT vs mammogram, US, CT, MRI, biopsy | Prospective | Newly diagnosed unilateral BC | Sensitivity, specificity | • Dual time point FDG-PET-CT improves discrimination between non-invasive and invasive cancers, and provided superior sensitivity for detecting small cancers and in dense breast.  
  • he ROC analysis s ggested ΔSUVma % of 8% as th e only significant cut-ff or discrimin n between invasive and non-invasive cancer (sensitivity 84.1%, specificity 75.9%, p < 0.0001) | Zytoon A, et al. 2008 |
| FDG-PET-CT mammogram vs MRI mammogram, biopsy | Retrospective | Initial age of BC | Change in management, sensitivity | • FDG-PET-CT and MRI did not differ for detection rate  
  • MRI correctly defined the T stage more often than did FDG PET-CT (77% vs 54%; p = 0.001) | Heusner T, et al. 2008 |
| Dual time FDG-PET vs mammogram, MRI, biopsy | Prospective | Newly diagnosed BC | Sensitivity | • Sensitivity of dual-time FDG-PET for detection of primary BC  
  o Invasive cancer >10 mm = 90%  
  o Invasive cancer 4-10 mm = 83%  
  o Non-invasive cancer = 77% | Mavi A, et al. 2006 |
| FDG-PET vs biopsy | Prospective | Newly diagnosed BC | Sensitivity, change in stage | • The sensitivities of FDG PET for detecting tumours according to TNM stages were:  
  o Stage O = 72%  
  o Stage I = 69%  
  o Stage II = 80%  
  o Stage III = 90%  
  o Stage IV = 92%  
  • FDG PET upgraded TNM stage in 9.2% of patients | Cermik T, et al. 2008 |
| Bone scan, chest radiography, liver US vs bone X-ray, CT, MRI | Retrospective | Newly diagnosed invasive BC | Sensitivity, specificity | • Bone scan vs chest radiography vs liver US  
  o Sensitivity = 100% vs 100% vs 100%  
  o Specificity = 94% vs 97% vs 94% | Puglisi F, et al. 2005 |

BC = breast cancer; CT = computed tomography; MRI = magnetic resonance imaging; NPV = negative predictive value; PET = positron emission tomography; p = p-value; ROC = receiver-operating characteristic; SUV = standardized uptake value; TNM = tumour, node, metastasis; US = ultrasound

New References Identified (alphabetic order):


Literature Search Strategies:

**Note:** Initially, these search strategies were used to identify studies evaluating breast MRI in addition to PET, bone scan, liver US, chest radiography. However, during the Breast DSG meeting on 11 June 2010, the group decided that the breast MRI studies would be better suited in a separate new guideline on Breast Imaging. Therefore, from the search results, the breast MRI studies were later excluded for Guideline 1-14.

**Medline**
1. exp "Sensitivity and Specificity"/
2. sensitivity.tw.
3. specificity.tw.
4. ((pre-test or pretest) adj probability).tw.
5. ((post-test or posttest) adj probability).tw.
6. predictive value$.tw.
7. likelihood ratio$.tw.
8. (change in stage or stage migration or upstag$ or downstag$).tw
9. or/1-8
10. (comment or letter or editorial or note or erratum or short survey or news or newspaper article or patient education handout or case report or historical article).pt.
11. 9 not 10
12. limit 11 to english
13. limit 12 to human
14. exp breast neoplasms/
15. ((cancer? or carcinoma? or neoplasm? or tumo?r) and (breast? or mammary)).tw.
16. 14 or 15
17. Neoplasm staging/ or neoplasm metastasis/ or stag$.tw. or baseline.tw. or preop$.tw.
18. 16 and 17
19. (MRI or magnetic resonance imag$).tw. or magnetic resonance imaging/ or (PET or positron emission tomograph$).tw. or positron-emission tomography /
20. (chest.tw and ((x-ray or radiogra$).tw or radiography/)) or (liver.tw and (ultraso$.tw or ultrasonography/)) or (bone and (scan$ or scintigraph$)).tw
21. 19 or 20
22. 18 and 21
23. 13 and 22
24. (200304$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$).ed.
25. 23 and 24

**Embase**
1. exp "Sensitivity and Specificity"/
2. sensitivity.tw.
3. specificity.tw.
4. ((pre-test or pretest) adj probability).tw.
5. ((post-test or posttest) adj probability).tw.
6. predictive value$.tw.
7. likelihood ratio$.tw.
8. "Diagnostic Accuracy/"
9. (change in stage or stage migration or upstag$ or downstag$).tw
10. or/1-9
11. (comment or letter or editorial or note or erratum or short survey or news or newspaper article or patient education handout or case report or historical article).pt.
12. 10 not 11
13. limit 12 to english
14. limit 13 to human
15. exp breast neoplasms/
16. ((cancer? or carcinoma? or neoplasm? or tumo?r) and (breast? or mammary)).tw.
| 17. | 15 or 16 |
| 18. | Neoplasm staging/ or neoplasm metastasis/ or stag$.tw. or baseline.tw. or preop$.tw. |
| 19. | 17 and 18 |
| 20. | (MRI or magnetic resonance imag$).tw. or magnetic resonance imaging/ or (PET or positron emission tomograph$).tw. or positron-emission tomography/ |
| 21. | (chest.tw and ((x-ray or radiogra$).tw or radiography/)) or (liver.tw and (ultraso$.tw or ultrasonography/)) or (bone and (scan$ or scintigraph$)).tw |
| 22. | 20 or 21 |
| 23. | 19 and 22 |
| 24. | 14 and 23 |
| 25. | (200314$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$).ew. |
| 26. | 24 and 25 |


**San Antonio Breast Cancer Symposium** - MRI and stag*; MRI and diagnos*; PET and stag*; PET and diagnos*; radiograph* or x-ray and stag*; radiograph* or x-ray and diagnos*; bone and scan and stag*; bone and scan and diagnos*; ultraso* and stag*; ultraso* and diagnos*

**Go to 6.**

6. Are the volume and content of the newly identified evidence such that a new document is necessary to address the topic?

| 6. NO |
| If Yes, then the document should be ARCHIVED with no further action; go to 11. If No, go to 7. |

7. On initial review, does the newly identified evidence support the existing recommendations? Do the current recommendations cover all relevant subjects addressed by the evidence, such that no new recommendations are necessary? Answer Yes or No, and explain if necessary:

| 7. YES |
| - There is no need to update the guideline on liver US, chest x-ray, and bone scanning because they are older, well-established techniques that did not generate much data with this updated search and will be very unlikely to generate any new data in future — the existing guideline adequately addressed these techniques. |
| - Although the PET data is new, there is no urgency to update the guideline with this new information at this time — the DART form, which will be attached to the guideline, is sufficient for readers to be aware of the new PET data. |
| - Therefore, Guideline 1-14 can be ENDORSED. |
| If Yes, the document can be ENDORSED. If No, go to 8. |

8. Does any of the newly identified evidence, on initial review, contradict the current recommendations, such that the current recommendations may cause harm or lead to unnecessary or improper treatment if followed? Answer Yes or No, and explain if necessary, citing newly identified references:

| 8. Not applicable. |
| If Yes, a WARNING note will be placed on the web site. If No, go to 9. |

9. Is there a good reason (e.g., new stronger evidence will be published soon, changes to current recommendations are trivial or address very limited situations) to postpone updating the guideline? Answer Yes or No, and explain if necessary:

| 9. Not applicable. |
| If Yes, the document update will be DEFERRED, indicating that the document can be used for decision making and the update will be deferred until the expected evidence becomes available. If No, go to 10. |
10. An update should be initiated as soon as possible. List the expected date of completion of the update:

10. Not applicable.  
An UPDATE will be posted on the website, indicating an update is in progress.

11. Circulate this form to the appropriate Disease Site Group for their approval. Once approved, a copy of this form should be placed behind the cover page of the current document on the website. Notify the original authors of the document about this review.

<table>
<thead>
<tr>
<th>DSG Approval Date:</th>
<th>Oct 11 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comments from DSG members</strong></td>
<td>Given that no new evidence is likely to arise, it is the consensus of the group that CT is a reasonable alternative in high risk (stage III) women.</td>
</tr>
</tbody>
</table>

STEP 2: First teleconference to determine:
- the clinical relevance of the guideline,
- if a new literature search is needed, and
- if Yes, the search criteria.

#1. Is there still a NEED for a guideline covering one or more of the topics in this document?

Yes → ARCHIVE

No → STEP 3: A NEW literature search based on input from #5 will be conducted, and the result will be sent to the reviewers with a follow-up date

#2. Are all the current recommendations based on the current questions definitive* or sufficient§, and have less than 5 years elapsed since the latest search?

Yes → ENDORSE

No → DEFERRAL

#3. Is there expected or known evidence that contradicts the current recommendations, such that they may cause harm or lead to unnecessary or improper treatment if followed?

Yes → WARNING

No → TELECONFERENCE with the reviewer(s) will focus the discussion on #5: the search strategies, i.e., scope, key word(s), and inclusion and exclusion criteria.

#4. Do current resources allow for an updated literature search to be conducted at this time?

Yes → NEW SEARCH

No → DEFERRAL

#5. List any new and relevant questions that have arisen since the last version of the document. List any changes to the original research questions that now must be considered. Determine the search criteria.

RC emails DSG reviewer(s) the DART protocol

Please note: No teleconference needed, IF the answers lead to one of these outcomes, PLUS the reviewer(s) complete & return the DART form with the answers & explanations.

DISCUSS DART questions #1-5
FLOW CHART (cont.)

### STEPS

#### STEP 4: Second teleconference to determine the ultimate status of the document

<table>
<thead>
<tr>
<th>Question</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>#6. Are the volume and content of the newly identified evidence such that a new document is necessary to address the topic?</td>
<td>Archive</td>
</tr>
<tr>
<td>#7. Does the newly identified evidence support the existing recommendations? Do the current recommendations cover all relevant subjects addressed by the evidence, such that no new recommendations are necessary?</td>
<td>Endorse</td>
</tr>
<tr>
<td>#8. Does any of the newly identified evidence, on initial review, contradict the current recommendations, such that the current recommendations may cause harm or lead to unnecessary or improper treatment if followed?</td>
<td>Warning</td>
</tr>
<tr>
<td>#9. Is there a good reason (e.g., new, stronger evidence will be published soon, changes to current recommendations are trivial or address very limited situations) to postpone updating the guideline?</td>
<td>Deferral</td>
</tr>
<tr>
<td>#10. An update should be initiated as soon as possible. List the expected date of completion of the update.</td>
<td>Update</td>
</tr>
</tbody>
</table>

#### STEP 5: Final outcome approval; Document Assessment & Review questions #11

<table>
<thead>
<tr>
<th>Question</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>#11. Circulate this form, the new evidence, and a draft document for approval by the appropriate DSG. Once approved, a copy of this form should be placed behind the cover page of the current document on the Web site. Notify the original authors of the document about this review.</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Please note:

- No teleconference needed, IF the reviewer(s) complete and return the DART form with answers & explanations.
- Teleconference with the reviewer(s) to discuss the type of update, priority, and resources.
DOCUMENT ASSESSMENT AND REVIEW DEFINITIONS

Document Assessment and Review Terms

* DEFINITIVE RECOMMENDATIONS - Definitive means that the current recommendations address the relevant subject area so fully that it would be very surprising to identify any contradictory or clarifying evidence.

$ SUFFICIENT RECOMMENDATIONS - Sufficient means that the current recommendations are based on consensus, opinion and/or limited evidence, and the likelihood of finding any further evidence of any variety is very small (e.g., in rare or poorly studied disease).

¶ WARNING - A warning indicates that, although the topic is still relevant, there may be, or is, new evidence that may contradict the guideline recommendations or otherwise make the document suspect as a guide to clinical decision making. The document is removed from the Web site, and a warning is put in its place. A new literature search may be needed, depending on the clinical priority and resources.

Document Assessment and Review Outcomes

1. ARCHIVED - An archived document is a document that will no longer be tracked or updated but may still be useful for academic or other informational purposes. The document is moved to a separate section of the Web site and each page is watermarked with the phrase “ARCHIVED”.

2. ENDORSED - An endorsed document is a document that the DSG/GDG has reviewed for currency and relevance and determined to be still useful as guidance for clinical decision making. A document may be endorsed because the DSG/GDG feels the current recommendations and evidence are sufficient, or it may be endorsed after a literature search uncovers no evidence that would alter the recommendations in any important way.

3. DEFERRAL - A Deferral means that the clinical reviewers feel that the document is still useful and the decision has been made to postpone further action for a number of reasons. The reasons for the deferral are in the Document Assessment and Review Tool (Appendix 2).

4. UPDATE - An Update means that the DSG/GDG recognizes that there is new evidence that makes changes to the existing recommendations in the guideline necessary but these changes are more involved and significant than can be accomplished through the Document Assessment and Review process. The DSG/GDG will rewrite the guideline at the earliest opportunity to reflect this new evidence. Until that time, the document will still be available as its existing recommendations are still of some use in clinical decision making.